SESSION 3:
Future Financing of Drug Discovery
09:00
Introduction by Session Chair
09:05
Title of talk to be announced
Mr Matthias BUCHER
CEPTON STRATEGIES, Paris, France
09:45
Title of talk to be announced
Mrs Magali RICHARD
HOME BIOSCIENCES, Paris, France
10:25
Coffee Break & Exhibition
10:55
Round-table discussion: Future Financing of Drug Discovery
SESSION 4 (Part 1):
Unmet Therapeutic Needs: Current Challenges
11:40
Introduction by Session Chair
11:45
Challenges and Opportunities in Cancer Therapy: a Perspective Across Modalities
Dr Tobias SCHMELZLE
NOVARTIS, Basel, Switzerland
Tobias Schmelzle earned an MSc from ETH Zurich, a PhD from the Biozentrum at University of Basel (TOR signaling, advisor Mike Hall) and completed his postdoctoral studies on 3D breast cancer models at Harvard Medical School (advisor Joan Brugge).
Having started in Novartis Biomedical Research Oncology in 2007 in the Target Identification and Validation (TIDVal) group, Tobias worked on several early programs and co-lead the global TIDVal group, which completed large-scale functional genomics campaigns, such as project DRIVE. Prior to embarking on his current role in 2021, Tobias was also a Drug Discovery Biology Group Leader serving on the local Oncology Leadership Team and a Project Team Leader of the YAP/TEAD LMW program (clinical development candidate NVP-IAG933). At current, Tobias is the Head of Oncology Drug Discovery in Basel and collaborates closely with the Oncology Radioligand Therapy group, while as a member of the global Novartis Biomedical Research Oncology Leadership Team contributing to the strategy and portfolio across multiple cancer indications and therapeutic modalities.
12:25
Gene Therapy of Rare Diseases. A Quantum Leap in Medicine.
Dr Serge BRAUN
AFM TÉLÉTHON, Evry, France
13:05
Lunch & Networking
SESSION 1 (Part 2):
Present and Future Tools for Drug Discovery
14:40
Introduction by Session Chair
14:45
Title of talk to be announced
Dr Dave HALLETT
EXSCIENTIA LTD, Oxford, United Kingdom
15:25
Title of talk to be announced
Dr Maria M. FLOCCO
ASTRAZENECA, Cambridge, United Kingdom
SESSION 5 (Part 1):
Vision for the Future of Drug Discovery
16:05
Introduction by Session Chair
16:10
Title of talk to be announced - virtual lecture
Dr Frank LAUKIEN
BRUKER, Billerica, United States
Dr Falko BUSSE
BRUKER SWITZERLAND, Fällanden, Switzerland
16:50
Coffee Break & Exhibition
17:20
25 Years of Thinking Small
Dr Harren JHOTI
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
18:00
Adding Years of Life and Quality of Life: How the Healthcare Industry Can Bring Value to the World
Dr Paul STOFFELS
GALAPAGOS, Beerse, Belgium